Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients

被引：0

作者：

Nishio, Minako ^{[1
]}

Kojitani, Yoshiki ^{[1
]}

Kitashiro, Saya ^{[1
]}

Ishiduka, Yasunobu ^{[1
]}

Otsuka, Tomoyuki ^{[1
]}

Nishida, Naohiro ^{[1
]}

Fujisawa, Fumie ^{[1
]}

Sugimoto, Naotoshi ^{[1
]}

Yagi, Toshinari ^{[1
]}

Souma, Ai ^{[2
]}

Kanaoka, Haruka ^{[2
]}

Oyamayama, Yuri ^{[2
]}

Taniguchi, Azusa ^{[2
]}

Nakajima, Satomi ^{[2
]}

Seto, Yukiko ^{[2
]}

Kusama, Hiroki ^{[2
]}

Watanabe, Noriyuki ^{[2
]}

Matsui, Saki ^{[2
]}

Nakayama, Takahiro ^{[2
]}

Kudou, Toshihiro ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Osaka Prefectural Hosp Org, Dept Med Oncol, Osaka, Japan

[2] Osaka Int Canc Inst, Osaka Prefectural Hosp Org, Dept Breast Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.3098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P67-5

引用

页码：S1465 / S1465

页数：1

共 50 条

[41] ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
Chen, Margaret
Li, Bin
Wang, Ye
Hu, Xichun
Tao, Zhonghua
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors
Chen, Xin-Yu
Li, Bin
Wang, Ye
Jin, Juan
Yang, Yu
Huang, Lei-Huan
Yang, Meng-Di
Zhang, Jian
Wang, Bi-Yun
Shao, Zhi-Ming
Ni, Ting
Huang, Sheng-Lin
Hu, Xi-Chun
Tao, Zhong-Hua
CANCER COMMUNICATIONS, 2023, 43 (09) : 1003 - 1026
[43] Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Thomas, Remy
Al-Khadairi, Ghaneya
Decock, Julie
FRONTIERS IN ONCOLOGY, 2021, 10
[44] Mechanisms of immune evasion in triple-negative breast cancer patients.
Orozco, Javier Ignacio
Manughian-Peter, Ayla O.
Salomon, Matthew P.
O'Day, Steven
Hoon, Dave S. B.
Marzese, Diego M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Where do the immune checkpoint inhibitors stand in the management of triple negative breast cancer?
El Rassy, Elie
El Karak, Fadi
Ghosn, Marwan
IMMUNOTHERAPY, 2018, 10 (04) : 247 - 250
[46] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Heeke, Arielle L.
Tan, Antoinette R.
CANCER AND METASTASIS REVIEWS, 2021, 40 (02) : 537 - 547
[47] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Arielle L. Heeke
Antoinette R. Tan
Cancer and Metastasis Reviews, 2021, 40 : 537 - 547
[48] Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis
Gao, Xin
Zhu, Ying
Wang, Peipei
Yu, Lulin
Ruan, Shanming
Shen, Minhe
Zhang, Kai
CANCER MEDICINE, 2023, 12 (24): : 21873 - 21884
[49] BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
不详
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (04) : 343 - 343
[50] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
Geenen, Jill J. J.
Linn, Sabine C.
Beijnen, Jos H.
Schellens, Jan H. M.
CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437

← 1 2 3 4 5 →